about
The learning curve for robotic distal pancreatectomy: an analysis of outcomes of the first 100 consecutive cases at a high-volume pancreatic centreRobotic pancreaticoduodenectomy in the presence of aberrant or anomalous hepatic arterial anatomy: safety and oncologic outcomes.250 robotic pancreatic resections: safety and feasibilityOutcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution.Cyst Gastrostomy and Necrosectomy for the Management of Sterile Walled-Off Pancreatic Necrosis: a Comparison of Minimally Invasive Surgical and Endoscopic Outcomes at a High-Volume Pancreatic Center.Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy.A pancreatic cancer multidisciplinary clinic: insights and outcomes.Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998-2011.Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.Safety and feasibility of the robotic platform in the management of surgical sequelae of chronic pancreatitis.Institutional Experience with Ostomies Created During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion.Current concepts in molecular genetics and management guidelines for pancreatic cystic neoplasms: an essential update for radiologists.Assessing the impact of conversion on outcomes of minimally invasive distal pancreatectomy and pancreatoduodenectomy.Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies.Cancer disparities in the COVID-19 era
P50
Q35761094-D685870D-97E1-494A-A4AA-CD97B534BCBBQ35761099-749E271A-2AE8-4D27-B033-B69179545FE6Q36204296-1FCB058D-B05B-4E37-B7D8-4D968C223896Q38156286-8DF73BF8-74F4-48F9-8AAC-A50A77F927B8Q38511762-7D47D2F2-6988-46CD-A238-5D675BC55298Q39148761-59668D7A-1FAD-4AF3-8CED-96E1DBCDE1B0Q39417171-A3DC8E78-7252-4F7E-A60A-0A91AE3CDCEEQ39731689-F53DDB2F-838D-442B-8BB9-D9BA9FBF7CC6Q40734231-A2467EA1-EFAB-44AF-BA5C-E23646B8BF9BQ40962389-9F3FAB45-A8F0-4BA0-9815-C41CA55B0795Q44892132-38BEEBE0-A123-4076-8FB6-A9AD77FFF2A9Q47186205-2D41C742-C4AB-4A10-A4F1-96CC023F2EFDQ47822308-1D4B53AF-2418-4949-8A87-CBCAFEF9F465Q48505692-A5055B14-9832-43F0-82A3-B97CC2F3BEACQ49388973-1EF21429-1C66-454C-9D11-4B3F7208A9F0Q50074174-1C7BE583-2342-4E79-927F-FE440A6998FDQ95836391-AA3CC547-81B5-4E16-849C-EF3F7CDEC934
P50
description
wetenschapper
@nl
name
Amer H Zureikat
@en
Amer H Zureikat
@nl
type
label
Amer H Zureikat
@en
Amer H Zureikat
@nl
prefLabel
Amer H Zureikat
@en
Amer H Zureikat
@nl
P31
P496
0000-0002-7800-5464